Clinical trials: Neoplastic Syndromes, Hereditary
Brain and Central Nervous System Tumors, Chordoma
Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
RATIONALE: Polyvinylpyrrolidone-sodium hyaluronate gel may lessen the pain of oral mucositis, or mouth sores, in patients undergoing treatment for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chordoma, Kidney Cancer, Leukemia
- Trial name
- NCT00349024
- Testing
- polyvinylpyrrolidone-sodium hyaluronate gel
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Healthy
Length of Adaptation and Threonine Requirement
This study aims to determine if the body's needs for threonine (an amino acid which is an essential building block for protein) is different when assessed after 1, 3 or 6 days of adaptation to the level of threonine intake being…
- Trial name
- NCT04585087
- Testing
- Dietary Intakes
- Where
- Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Basal Cell Nevus Syndrome
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Multicenter, double-blind, randomized, vehicle-controlled study that evaluates the efficacy and safety of patidegib gel 2% and 4% in comparison with vehicle in participants at least 18 years of age that meet the diagnostic…
- Trial name
- NCT02762084
- Testing
- Patidegib, Vehicle gel
- Where
- 2 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- PellePharm, Inc.
Advanced Breast Cancer
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.
- Trial name
- MONALEESA-3 (NCT02422615)
- Testing
- Ribociclib, Fulvestrant
- Where
- 174 sites in United States, Australia and 28 more
- Volunteers
- 726 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma
Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
This 22 week study will assess the efficacy, safety, and tolerability of LDE225 versus vehicle when applied topically to basal cell carcinoma (BCC) in patients with NBCCS. Patients will treat multiple BCCs for up to 12 weeks.
- Trial name
- NCT03070691
- Testing
- LDE225B, Vehicle
- Where
- 35 sites in Belgium, Canada and 8 more
- Sponsor
- Novartis Pharmaceuticals
Neoplastic Syndromes, Hereditary, Prostatic Neoplasms
Familial Prostate Cancer
The purpose of this study is to identify affected individuals in families with prostate cancer and to use this information to identify genetic markers closely-linked to the disease gene.
- Trial name
- NCT00001377
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Adenomatous Polyposis Coli
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Background: Saliva, blood, tissue, and cancer contain DNA. DNA makes the "instruction book" for the cells in the body. Cancer is caused by changes in DNA that affect cell function.
- Conditions
- Neoplasms, Adenomatous Polyposis Coli, Neurofibroma, Plexiform, Myelodysplastic Syndromes
- Trial name
- NCT03027401
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Li Fraumeni Syndrome
LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)
The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.
- Trial name
- LIFSCREEN (NCT01464086)
- Testing
- whole body MRI
- Where
- France
- Volunteers
- 107 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer, BRCA Mutation
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes and Mis-Match Repair genes (MLH1, MSH6…
- Conditions
- Prostate Cancer, BRCA Mutation, Mismatch Repair Gene Mutation, Genetic Predisposition to Disease
- Trial name
- NCT00261456
- Testing
- PSA test, Prostate Biopsy
- Where
- United Kingdom
- Volunteers
- 3,500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Ulcerative Colitis, Familial Adenomatous Polyposis
Ten Versus Fifteen Centimeter Pouch in IPAA Surgery
The aim of this randomized controlled trial is to compare outcome after construction of an ileal (J-shaped) reservoir of 10 versus 15 centimeters in primary ileal pouch-anal anastomosis surgery.
- Trial name
- TESTIMONY (NCT06538402)
- Testing
- 10 cm pouch, 15 cm pouch
- Where
- 2 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- Odense University Hospital
Tuberous Sclerosis Complex
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
The purpose of the RaRE-TS study is to determine safety, tolerability and efficacy of rapamycin versus placebo in a drug resistant epilepsy associated with tuberous sclerosis complex (TSC).
- Trial name
- RaRE-TS (NCT05534672)
- Testing
- Rapamycin
- Where
- 2 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Katarzyna Kotulska
Neurofibromatosis Type 2, Vestibular Schwannomas
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry.
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannomas, Meningiomas
- Trial name
- NCT01880749
- Testing
- RAD001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00513474
- Testing
- busulfan, cyclophosphamide, cyclosporin-A
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Hereditary Breast and Ovarian Cancer Syndrome
Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
Young female counselees (18-40 years) belonging to HBOC families with a known mutation on BRCA-genes or not, receive a lot of information regarding their cancer risk. Information sources are numerous and sometimes contradictory.
- Trial name
- NCT02705924
- Testing
- psychoeducation
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Jean Perrin
Duodenum Cancer, Familial Adenomatous Polyposis
Duodenal Polyposis Classification in FAP
Duodenal cancer is the leading cause of cancer-related mortality in patients with familial adenomatous polyposis (FAP), yet the current Spigelman staging system provides limited predictive accuracy for advanced neoplasia.
- Conditions
- Duodenum Cancer, Familial Adenomatous Polyposis, Duodenal Polyposis, Ampulla of Vater Adenoma
- Trial name
- DRACO (NCT07199127)
- Testing
- DRACO
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Men, Health Behavior
POWERPLAY Phase 2: Development and Evaluation in Male-dominated Workplaces
With funding from the Alberta Ministry of Labour (Grant #095244772), a program called POWERPLAY (www.powerplayatwork.com), designed to promote men's health at work, will be evaluated in workplaces in Alberta.
- Conditions
- Men, Health Behavior, Mental Health Wellness 1, Health Knowledge, Attitudes, Practice
- Trial name
- NCT03781453
- Testing
- POWERPLAY
- Where
- 3 sites in Canada
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Joan Bottorff
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Leukemia, Myelodysplastic Syndromes
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00064090
- Testing
- cytarabine, triapine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Neoplastic Syndromes, Hereditary
Applying Population Management Best Practices to Preventative Genomic Medicine Trial
Preventive genomic medicine, particularly identification of individuals with inherited cancer risk, can improve longevity and quality of life, yet adherence to risk management following cancer genomic testing is poor.
- Trial name
- CARE-HCS (NCT07053813)
- Testing
- Web resources, Personalized outreach
- Where
- 2 sites in United States
- Volunteers
- 900 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.